AI assistant
Novonesis AS — Earnings Release 2024
Aug 27, 2024
3377_rns_2024-08-27_87817a67-b240-489f-ac23-26ae44a05732.pdf
Earnings Release
Open in viewerOpens in your device viewer
novonesis
Novonesis increases outlook for full year 2024
Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.
The 2024 outlook is increased to:
- Pro forma organic sales growth of now 7-8% (previously “upper end of 5-7”)
- Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously “35-36”)
Additional information is made available in the Company announcement: Interim Report H1 2024.
Company Announcement no. 26 – August 27, 2024
Novozymes A/S, part of Novonesis Group – Krogshojevej 36 2880 Bagsvaerd – Phone +45 4446 0000
CVR number: 10 00 71 27 – LEI: 529900T6WNZXD2R3JW38
Page 1/2
novonesis
Information regarding forward-looking statements
This announcement includes forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of the combined group and all of which are based on the combined group's current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "aim", "annualized", "anticipate", "assess", "assume", "believe", "continue", "could", "estimate", "expect", "goal", "hope", "intend", "may", "objective", "plan", "position", "potential", "predict", "project", "risk", "seek", "should", "target", "will" or "would" or the highlights or the negatives thereof, other variations thereon or comparable terminology. The forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and other documents regarding the combination and include statements that reflect the combined group's intentions, beliefs, or current expectations and projections about their respective future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, targets, strategies, and opportunities, as well as the markets in which they respectively operate. The forward-looking statements and other statements contained in this announcement regarding matters that are not historical facts involve predictions. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the combined group. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed, or implied in such forward-looking statements. Forward-looking statements in this announcement speak only as of the date of this announcement. The information contained in this announcement is subject to change without notice, and, except as required by applicable laws and regulations, the combined group expressly disclaims any obligation or undertaking to update or revise the forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions, or circumstances on which such statements are based, and nor does it intend to. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement. As a result of these risks, uncertainties, and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.
Contact Information
Investor Relations
Tobias Bjorklund +45 3077 8682 [email protected]
Anders Enevoldsen +45 5350 1453 [email protected]
Media Relations
Lina Danstrup +45 3077 0552 [email protected]
Novonesis is a global company leading the era of biosolutions.
By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.
Novozymes A/S, part of
Novonesis Group
Krogshoejvej 36
2880 Bagsvaerd
Denmark
novonesis.com